In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NIH Translational Science Center Becomes A (Cash-limited) Reality

Executive Summary

NIH receives more than one-half billion dollars to finance activities of the National Center for Advancing Translational Science, which came into being when President Obama signed a consolidated fiscal 2012 appropriations bill Dec. 23. House and Senate members who negotiated the final bill cautioned that NCATS’ efforts to find ways to speed up drug development should not inhibit private efforts in the same arena.

You may also be interested in...

Pfizer CTI Research Network Expands With NIH Collaboration

The partnership, announced Dec. 4, marks the first time a U.S. government agency has entered into a collaborative arrangement to conduct research through Pfizer’s Centers for Therapeutic Innovation network.

NIH Drug Development Strategy Gets First Candidate Through Valley Of Death

AesRx and its potential treatment for sickle cell disease are acquired by Baxter International, a measure of validation for the NCATS model of de-risking product development for rare and neglected diseases.

FDA, NIH Devise Regulatory Research Agenda, Look For Financing

The sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Science Director Christopher Austin noted during a June 25 teleconference to discuss Institute of Medicine recommendations for strengthening the Clinical and Translation Science Awards program.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts